Effects of celecoxib on prostanoid biosynthesis and circulating angiogenesis proteins in familial adenomatous polyposis

Journal of Pharmacology and Experimental Therapeutics

Volumn 341, Issue 1, 2012, Pages 242-250

  Dovizio, Melania ^a,b   Tacconelli, Stefania ^a,b   Ricciotti, Emanuela ^c   Bruno, Annalisa ^a,b   Maier, Thorsten Jürgen ^d   Anzellotti, Paola ^a,b   Di Francesco, Luigia ^a,b   Sala, Paola ^e   Signoroni, Stefano ^e   Bertario, Lucio ^e   Dixon, Dan A ^f   Lawson, John A ^c   Steinhilber, Dieter ^d   FitzGerald, Garret A ^c   Patrignani, Paola ^a,b  

^a UNIVERSITY OF CHIETI   (Italy)

^b Center of Excellence on Aging   (Italy)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d GOETHE UNIVERSITY   (Germany)

^e NATIONAL CANCER INSTITUTE   (Italy)

^f UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

11 ALPHA HYDROXY 9,15 DIOXO 2,3,4,5 TETRANOR PROSTANE 1,20 DIOIC ACID; 11 OXOTHROMBOXANE B2; 2,3 DINOR 6 OXOPROSTAGLANDIN F1 ALPHA; ACETYLSALICYLIC ACID; ANGIOGENIC PROTEIN; ANGIOGENIN; ANGIOPOIETIN 1; ANGIOPOIETIN 2; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; FIBROBLAST GROWTH FACTOR 2; GROWTH FACTOR; INTERCELLULAR ADHESION MOLECULE 1; KERATINOCYTE GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR BB; PROSTACYCLIN; PROSTAGLANDIN E2; PROSTANOID; THROMBOXANE A2; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; UNCLASSIFIED DRUG; VASCULOTROPIN A; VASCULOTROPIN D;

ADENOMATOUS POLYP; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ARTICLE; CARCINOMA CELL; CLINICAL ARTICLE; COCULTURE; COLON ADENOCARCINOMA; CONTROLLED STUDY; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYMURIA; FAMILIAL ADENOMATOUS POLYPOSIS; FAMILIAL DISEASE; FEMALE; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS INHIBITION; PROTEIN BLOOD LEVEL; PROTEIN SYNTHESIS INHIBITION; PROTEIN URINE LEVEL; THROMBOCYTE ACTIVATION; TUMOR VASCULARIZATION;

ADENOMATOUS POLYPOSIS COLI; ADULT; ANIMALS; CYCLOOXYGENASE 2 INHIBITORS; EPOPROSTENOL; FEMALE; HT29 CELLS; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MIDDLE AGED; NEOVASCULARIZATION, PHYSIOLOGIC; PROSTAGLANDINS; PYRAZOLES; SULFONAMIDES; THROMBOXANE A2; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84858639105     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.111.190785     Document Type: Article

References (44)

1. Albert D, Zündorf I, Dingermann T, Müller WE, Steinhilber D, and Werz O (2002) Hyperforin is a dual inhibitor of cyclooxygenase-1 and 5-lipoxygenase. Biochem Pharmacol 64:1767-1775. (Pubitemid 35355728)
2. Binnie V, McHugh S, Macpherson L, Borland B, Moir K, and Malik K (2004) The validation of self-reported smoking status by analysing cotinine levels in stimulated and unstimulated saliva, serum and urine. Oral Dis 10:287-293. (Pubitemid 39295441)
3. Charman WN, Charman SA, Monkhouse DC, Frisbee SE, Lockhart EA, Weisman S, and Fitzgerald GA (1993) Biopharmaceutical characterisation of a low-dose (75 mg) controlled-release aspirin formulation. Br J Clin Pharmacol 36:470-473. (Pubitemid 23344160)
4. Ciabattoni G, Maclouf J, Catella F, FitzGerald GA, and Patrono C (1987) Radioimmunoassay of 11-dehydrothromboxane B2 in human plasma and urine. Biochim Biophys Acta 918:293-297. (Pubitemid 17065554)
5. Coppinger JA, O'Connor R, Wynne K, Flanagan M, Sullivan M, Maguire PB, Fitzgerald DJ, and Cagney G (2007) Moderation of the platelet releasate response by aspirin. Blood 109:4786-4792. (Pubitemid 46827772)
6. Csiki I, Morrow JD, Sandler A, Shyr Y, Oates J, Williams MK, Dang T, Carbone DP, and Johnson DH (2005) Targeting cyclooxygenase-2 in recurrent non-small cell lung cancer: a phase II trial of celecoxib and docetaxel. Clin Cancer Res 11:6634-6640. (Pubitemid 41339004)
7. De Bock K, Cauwenberghs S, and Carmeliet P (2011) Vessel abnormalization: another hallmark of cancer? Molecular mechanisms and therapeutic implications. Curr Opin Genet Dev 21:73-79.
8. Di Francesco L, Totani L, Dovizio M, Piccoli A, Di Francesco A, Salvatore T, Pandolfi A, Evangelista V, Dercho RA, Seta F, et al. (2009) Induction of prostacyclin by steady laminar shear stress suppresses tumor necrosis factor-α biosynthesis via heme oxygenase-1 in human endothelial cells. Circ Res 104:506-513.
9. Donnini S, Finetti F, Solito R, Terzuoli E, Sacchetti A, Morbidelli L, Patrignani P, and Ziche M (2007) EP2 prostanoid receptor promotes squamous cell carcinoma growth through epidermal growth factor receptor transactivation and iNOS and ERK1/2 pathways. FASEB J 21:2418-2430. (Pubitemid 47230672)
10. Duffield-Lillico AJ, Boyle JO, Zhou XK, Ghosh A, Butala GS, Subbaramaiah K, Newman RA, Morrow JD, Milne GL, and Dannenberg AJ (2009) Levels of prostaglandin E metabolite and leukotriene E4 are increased in the urine of smokers: Evidence that celecoxib shunts arachidonic acid into the 5-lipoxygenase pathway. Cancer Prev Res (Phila) 2:322-329.
11. Fiore E, Fusco C, Romero P, and Stamenkovic I (2002) Matrix metalloproteinase 9 (MMP-9/gelatinase B) proteolytically cleaves ICAM-1 and participates in tumor cell resistance to natural killer cell-mediated cytotoxicity. Oncogene 21:5213-5223. (Pubitemid 34948133)
12. FitzGerald GA, Pedersen AK, and Patrono C (1983) Analysis of prostacyclin and thromboxane biosynthesis in cardiovascular disease. Circulation 67:1174-1177. (Pubitemid 13105335)
13. Gay LJ and Felding-Habermann B (2011) Contribution of platelets to tumour metastasis. Nat Rev Cancer 11:123-134.
14. Gismondi V, Meta M, Bonelli L, Radice P, Sala P, Bertario L, Viel A, Fornasarig M, Arrigoni A, Gentile M, et al. (2004) Prevalence of the Y165C, G382D and 1395del-GGA germline mutations of the MYH gene in Italian patients with adenomatous polyposis coli and colorectal adenomas. Int J Cancer 109:680-684. (Pubitemid 38405614)
15. Grosser T, Fries S, and FitzGerald GA (2006) Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest 116:4-15. (Pubitemid 43121782)
16. Hanahan D and Folkman J (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86:353-364. (Pubitemid 26272076)
17. Honn KV (1983) Inhibition of tumor cell metastasis by modulation of the vascular prostacyclin/thromboxane A2 system. Clin Exp Metastasis 1:103-114.
18. Italiano JE Jr, Richardson JL, Patel-Hett S, Battinelli E, Zaslavsky A, Short S, Ryeom S, Folkman J, and Klement GL (2008) Angiogenesis is regulated by a novel mechanism: pro- and antiangiogenic proteins are organized into separate platelet α granules and differentially released. Blood 111:1227-1233. (Pubitemid 351213404)
19. Jiang W, Hiscox S, Matsumoto K, and Nakamura T (1999) Hepatocyte growth factor/scatter factor, its molecular, cellular and clinical implications in cancer. Crit Rev Oncol Hematol 29:209-248. (Pubitemid 29158969)
20. Jurasz P, Alonso-Escolano D, and Radomski MW (2004) Platelet-cancer interactions: mechanisms and pharmacology of tumour cell-induced platelet aggregation. Br J Pharmacol 143:819-826. (Pubitemid 39664840)
21. McAdam BF, Byrne D, Morrow JD, and Oates JA (2005) Contribution of cyclooxygenase-2 to elevated biosynthesis of thromboxane A2 and prostacyclin in cigarette smokers. Circulation 112:1024-1029. (Pubitemid 41170271)
22. Menter DG, Onoda JM, Moilanen D, Sloane BF, Taylor JD, and Honn KV (1987) Inhibition by prostacyclin of the tumor cell-induced platelet release reaction and platelet aggregation. J Natl Cancer Inst 78:961-969. (Pubitemid 17093022)
23. Moser AR, Luongo C, Gould KA, McNeley MK, Shoemaker AR, and Dove WF (1995) ApcMin: a mouse model for intestinal and mammary tumorigenesis. Eur J Cancer 31A:1061-1064.
24. Murphey LJ, Williams MK, Sanchez SC, Byrne LM, Csiki I, Oates JA, Johnson DH, and Morrow JD (2004) Quantification of the major urinary metabolite of PGE2 by a liquid chromatographic/mass spectrometric assay: determination of cyclooxygenase-specific PGE2 synthesis in healthy humans and those with lung cancer. Anal Biochem 334:266-275. (Pubitemid 39370961)
25. Pacienza N, Pozner RG, Bianco GA, D'Atri LP, Croci DO, Negrotto S, Malaver E, Gómez RM, Rabinovich GA, and Schattner M (2008) The immunoregulatory glycan-binding protein galectin-1 triggers human platelet activation. FASEB J 22: 1113-1123. (Pubitemid 351519966)
26. Padua D, Zhang XH, Wang Q, Nadal C, Gerald WL, Gomis RR, and Massagué J (2008) TGFβ primes breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell 133:66-77. (Pubitemid 351442989)
27. Patrignani P, Panara MR, Greco A, Fusco O, Natoli C, Iacobelli S, Cipollone F, Ganci A, Créminon C, Maclouf J, et al. (1994) Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases. J Pharmacol Exp Ther 271:1705-1712. (Pubitemid 24382690)
28. Patrono C, Ciabattoni G, Pinca E, Pugliese F, Castrucci G, De Salvo A, Satta MA, and Peskar BA (1980) Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects. Thromb Res 17:317-327. (Pubitemid 10129020)
29. Patrono C, García Rodríguez LA, Landolfi R, and Baigent C (2005) Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 353:2373-2383. (Pubitemid 41713749)
30. Patrono C, Patrignani P, and García Rodríguez LA (2001) Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs. J Clin Invest 108:7-13. (Pubitemid 32634915)
31. Powell SM, Zilz N, Beazer-Barclay Y, Bryan TM, Hamilton SR, Thibodeau SN, Vogelstein B, and Kinzler KW (1992) APC mutations occur early during colorectal tumorigenesis. Nature 359:235-237.
32. 2synthase antithetically altered tumor angiogenesis and tumor growth. Cancer Res 62:63-66.
33. Prescott SM (2000) Is cyclooxygenase-2 the alpha and the omega in cancer? J Clin Invest 105:1511-1513.
34. Rothwell PM, Fowkes FG, Belch JF, Ogawa H, Warlow CP, and Meade TW (2011) Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 377:31-41.
35. Schiffmann S, Sandner J, Schmidt R, Birod K, Wobst I, Schmidt H, Angioni C, Geisslinger G, and Grösch S (2009) The selective COX-2 inhibitor celecoxib modulates sphingolipid synthesis. J Lipid Res 50:32-40.
36. Schönberger F, Heinkele G, Mürdter TE, Brenner S, Klotz U, and Hofmann U (2002) Simple and sensitive method for the determination of celecoxib in human serum by high-performance liquid chromatography with fluorescence detection. J Chromatogr B Analyt Technol Biomed Life Sci 768:255-260. (Pubitemid 34158860)
37. Sciulli MG, Filabozzi P, Tacconelli S, Padovano R, Ricciotti E, Capone ML, Grana M, Carnevale V, and Patrignani P (2005) Platelet activation in patients with colorectal cancer. Prostaglandins Leukot Essent Fatty Acids 72:79-83. (Pubitemid 40051223)
38. Sheehan KM, Sheahan K, O'Donoghue DP, MacSweeney F, Conroy RM, Fitzgerald DJ, and Murray FE (1999) The relationship between cyclooxygenase-2 expression and colorectal cancer. JAMA 282:1254-1257. (Pubitemid 29468497)
39. Sieber OM, Lipton L, Crabtree M, Heinimann K, Fidalgo P, Phillips RK, Bisgaard ML, Orntoft TF, Aaltonen LA, Hodgson SV, et al. (2003) Multiple colorectal adenomas, classic adenomatous polyposis, and germ-line mutations in MYH. N Engl J Med 348:791-799. (Pubitemid 36245755)
40. Song WL, Lawson JA, Wang M, Zou H, and FitzGerald GA (2007) Noninvasive assessment of the role of cyclooxygenases in cardiovascular health: a detailed HPLC/MS/MS method. Methods Enzymol 433:51-72.
41. Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB, Wakabayashi N, Saunders B, Shen Y, Fujimura T, et al. (2000) The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342:1946-1952. (Pubitemid 30419089)
42. Stetler-Stevenson WG and Seo DW (2005) TIMP-2: an endogenous inhibitor of angiogenesis. Trends Mol Med 11:97-103. (Pubitemid 40348986)
43. Wang D and Dubois RN (2010) Eicosanoids and cancer. Nat Rev Cancer 10:181-193.
44. Yoshimatsu K, Golijanin D, Paty PB, Soslow RA, Jakobsson PJ, DeLellis RA, Subbaramaiah K, and Dannenberg AJ (2001) Inducible microsomal prostaglandin E synthase is overexpressed in colorectal adenomas and cancer. Clin Cancer Res 7:3971-3976. (Pubitemid 34044615)